Effects of mometasone furoate on the quality of life: A randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire

Clinical and Experimental Allergy

Volumn 41, Issue 3, 2011, Pages 417-423

  Baiardini, I ^a   Villa, E ^a   Rogkakou, A ^a   Pellegrini, S ^a   Bacic, M ^a   Compalati, E ^a   Braido, F ^a   Le Grazie, C ^b   Canonica, G W ^a   Passalacqua, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Medical Division   (Italy)

Author keywords

Intermittent asthma; Mometasone furoate nasal spray; Persistent rhinitis; Quality of life; Respiratory allergy

Indexed keywords

MOMETASONE FUROATE; NOSE SPRAY;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PERENNIAL RHINITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; RHINASTHMA QUESTIONNAIRE; SYMPTOM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNADIENEDIOLS; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC, PERENNIAL; YOUNG ADULT;

EID: 79551632901     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2010.03660.x     Document Type: Article

References (27)

1. Bousquet J, Van de Cauwenberge P., eds. Allergic rhinitis and its impact on Asthma (ARIA) WHO position paper. J Allergy Clin Immunol 2001; 108 (Suppl.):S147-334.
2. Demoly P, Allaert FA, Lecasble M, Bousquet JPRAGMA. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003; 58:672-5.
3. Ciprandi G, Cirillo I, Vizzaccaro A et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005; 60:882-7.
4. Blanc PD, Trupin L, Eisner M et al. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol 2001; 54:610-8.
5. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007; 120:381-7.
6. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004; 20:305-17.
7. Baiardini I, Pasquali M, Giardini A, Majani G, Canonica GW. Quality of life in respiratory allergy. Allergy Asthma Proc 2001; 22:177-81.
8. Bousquet J, Neukirch F, Bousquet PJ et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006; 117:158-62.
9. Bousquet J, Annesi-Maesano I, Carat F et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005; 35:728-32.
10. Cruz A. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62 (Suppl. 84):1-41.
11. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for Industry: patient reported outcome measures: use in medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes 2006; 4:79.
12. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP)., Reflection paper on the regulatory guidance for the use of health-related quality of life (HROL) measures in the evaluation of medicinal products. European Medicines Agency website, 2005. Available at (accessed 12 April 2007).
13. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999; 104:364-9.
14. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14:32-8.
15. Baiardini I, Pasquali M, Giardini A et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 2003; 58:289-94.
16. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317:1624-9.
17. Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE, Passalacqua G, Canonica GW. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008; 63:1280-91.
18. Global initiative for the management of asthma (GINA). Revised version 2006. Available at (accessed 10 May 2007).
19. Baiardini I, Braido F, Tarantini F et al. ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy 2008; 63:660-9.
20. Baiardini I, Bousquet PJ, Brzoza Z et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 2009; 65:290-5.
21. van Drunen C, Meltzer EO, Bachert C, Bousquet J, Fokkens WJ. Nasal allergies and beyond: a clinical review of the pharmacology, efficacy and safety of mometasone furoate. Allergy 2005; 60:5-19.
22. Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121:1824-32.
23. Ciprandi G, Canonica WG, Grosclaude M, Ostinelli J, Brazzola GG, Bousquet J. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002; 57:586-91.
24. Passalacqua G, Ciprandi G, Pasquali M, Guerra L, Canonica GW. An update on the asthma-rhinitis link. Curr Opin Allergy Clin Immunol 2004; 4:177-83.
25. Pedersen W, Hjuler I, Bisgaard H, Mygind N. Nasal inhalation of budesonide from a spacer in children with perennial rhinitis and asthma. Allergy 1998; 53:383-7.
26. Baena-Cagnani CE, Berger WE, DuBuske LM et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003; 130:307-13.
27. Taramarcaz P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev 2003: 003570.